Literature DB >> 16131979

Gastrointestinal outcomes and confounders in cystic fibrosis.

Drucy Borowitz, Peter R Durie, Lane L Clarke, Steven L Werlin, Christopher J Taylor, John Semler, Robert C De Lisle, Peter Lewindon, Steven M Lichtman, Maarten Sinaasappel, Robert D Baker, Susan S Baker, Henkjan J Verkade, Mark E Lowe, Virginia A Stallings, Morteza Janghorbani, Ross Butler, James Heubi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16131979     DOI： 10.1097/01.mpg.0000178439.64675.8d

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  43 in total

1.  Measures of Dietary Fat and Energy Absorption in Healthy Adults.

Authors:  Hillary Bashaw; Jefferson N Brownell; Joan I Schall; Virginia A Stallings
Journal:  Pancreas       Date:  2020-07       Impact factor: 3.327

2.  Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.

Authors:  Marjan Wouthuyzen-Bakker; Marcel J C Bijvelds; Hugo R de Jonge; Robert C De Lisle; Johannes G M Burgerhof; Henkjan J Verkade
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

3.  Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule.

Authors:  Daniel Gelfond; Changxing Ma; Jack Semler; Drucy Borowitz
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

Review 4.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

5.  The serological evidence in humans supports a negligible risk of zoonotic infection from porcine circovirus type 2.

Authors:  Peter D Burbelo; Jack A Ragheb; Amit Kapoor; Yanjin Zhang
Journal:  Biologicals       Date:  2013-10-10       Impact factor: 1.856

6.  The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Authors:  Manuele Furnari; Alessandra De Alessandri; Federico Cresta; Maria Haupt; Marta Bassi; Angela Calvi; Riccardo Haupt; Giorgia Bodini; Iftikhar Ahmed; Francesca Bagnasco; Edoardo Giovanni Giannini; Rosaria Casciaro
Journal:  J Gastroenterol       Date:  2018-09-19       Impact factor: 7.527

7.  Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.

Authors:  Gavin R Graff; John McNamara; James Royall; Steven Caras; Kristin Forssmann
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

8.  Development of a polarized pancreatic ductular cell epithelium for physiological studies.

Authors:  Yunxia O'Malley; Pavana G Rotti; Ian M Thornell; Oriana G Vanegas Calderón; Christopher Febres-Aldana; Katelin Durham; Jianrong Yao; Xiaopeng Li; Zheng Zhu; Andrew W Norris; Joseph Zabner; John F Engelhardt; Aliye Uc
Journal:  J Appl Physiol (1985)       Date:  2018-03-08

9.  Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis.

Authors:  Drucy Borowitz; Michael W Konstan; Anna O'Rourke; Morty Cohen; Leslie Hendeles; Frederick T Murray
Journal:  J Pediatr Pharmacol Ther       Date:  2007-01

10.  Defective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease.

Authors:  Jinghua Liu; Nancy M Walker; Akifumi Ootani; Ashlee M Strubberg; Lane L Clarke
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.